MarketIQ Analyst Report for Metagenomi, Inc. Common Stock

5959 HORTON STREET, 7TH FLOOR, EMERYVILLE, CA, UNITED STATES
MGX

Last Updated: 11 Nov 2024

Executive Summary

Metagenomi, Inc. (MGX) is a gene editing biotechnology company with a market capitalization of $101.058 million. The company's latest stock price is $2.02, with a 52-week high of $15 and a 52-week low of $1.85. Metagenomi's financial performance shows a revenue of $55.929 million, an EBITDA of -$83.549 million, and an EPS of -$2.00. The company has a strong analyst rating, with 1 "Strong Buy" and 5 "Buy" ratings.

Company Overview

Metagenomi, Inc. is headquartered in Emeryville, California. The company develops therapeutics for patients using metagenomics-derived genome editing toolbox. Metagenomi's mission is to use its proprietary technology to develop new treatments for diseases that are currently incurable.

Fundamental Analysis

Metagenomi's financial performance has been mixed. The company has reported a revenue of $55.929 million in the last twelve months, an increase of 0.765% year-over-year. However, the company's EBITDA was -$83.549 million, and its EPS was -$2.00. Metagenomi's profit margin is -1.341%, and its operating margin is -0.843%. The company's return on assets is -0.139%, and its return on equity is -0.29%.

Technical Analysis

Metagenomi's stock price has been trending down in recent months. The stock is currently trading below its 50-day moving average of $3.667 and its 200-day moving average of $6.80. The stock's relative strength index (RSI) is 30.00, which indicates that the stock is oversold.

Short Term Outlook

Metagenomi's stock price is likely to remain under pressure in the short term. The company's financial performance has been weak, and the stock is trading below its moving averages. The RSI also indicates that the stock is oversold.

Long Term Outlook

Metagenomi's long-term outlook is more positive. The company's technology has the potential to revolutionize the treatment of diseases. If Metagenomi can successfully develop new treatments for diseases that are currently incurable, the company's stock price could rise significantly.

Analyst Recommendations

Analysts are bullish on Metagenomi's long-term prospects. The company has a strong analyst rating, with 1 "Strong Buy" and 5 "Buy" ratings. The average analyst target price is $17.00, which represents a significant upside potential from the current stock price.